Ligustilide inhibits NSCLC glycolysis by mediating the PTEN/AKT signalling pathway and increasing caspase‐3, ‐7, resulting in reduced TME angiogenesis and increased tumour cell apoptosis [33]. The gene discussed is AKT1; the disease is non-small cell lung carcinoma.